(2011) Treatment of HER2-positive breast cancer: current status and future perspectives. Nature Reviews Clinical Oncology 9 , 16-32 /Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat ...
The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading to approval of the first HER2-targeted drug — the monoclonal
Breast cancer cells with higher than normal levels of HER2 are called HER2-positive. Such cancers tend to grow and spread faster than other breast cancers, but are much more likely to respond to treatment with drugs that target the HER2 protein. There are several her2 targeted therapies. What...
HER2-positive (+) breast cancer is an aggressive disease with poor prognosis, a narrative that changed drastically with the advent and approval of trastuzumab, the first humanized monoclonal antibody targeting HER2. In addition to another monoclonal anti
Dr Jain on Existing Challenges Within the TNBC Treatment Paradigm SABCS Highlights and Future Directions in the Treatment of Breast Cancer Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer Dr Fisch on the Incidence of Neutropenia With Sacituzumab Govitecan ...
The stage of your breast cancer (whether it has spread beyond the primary tumor site and into nearby tissue or organs, including the lymph nodes) is essential because it helps determine which treatment options are available. Your outlook is better if your cancer is at an early stage when i...
In the initialtrial, 406 patients withHER2-positive breast cancer with tumors 3 cm or smaller and negative nodes received weekly paclitaxel plus weekly trastuzumab for 12 weeks, followed by trastuzumab every 3 weeks for 9 months. (There wasn’t a control group because no standard of tre...
“There have been many advances in the development of drugs for HER2-positive breast cancer since the introduction of Herceptin (trastuzumab) in 1998. The approval of Enhertu represents the newest treatment option for patients who have progressed on available HER2-directed therapies...
Over the past decade, the management of HER2-positive breast cancer has evolved dramatically. In addition to advances in screening, genetic testing, imagin
Trastuzumab deruxtecan (T-DXd) is a highly effective drug for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced recurrent breast cancer. It was approved by the US Food and Drug Admninistration even though it had only been through a phase...